Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.46)
# 234
Out of 5,180 analysts
522
Total ratings
46.82%
Success rate
27.64%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $34 → $22 | $19.56 | +12.47% | 17 | Mar 31, 2026 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $4 → $7 | $6.03 | +16.18% | 16 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $53 → $74 | $58.15 | +27.26% | 6 | Mar 10, 2026 | |
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $8.46 | +18.20% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $16.23 | -7.58% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $27.70 | +22.74% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $730.25 | +28.72% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $23.56 | +44.31% | 5 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $45 → $48 | $40.23 | +19.31% | 28 | Feb 25, 2026 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $0.5 | $0.21 | +142.95% | 20 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $24.84 | +40.90% | 24 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $13 | $4.11 | +216.30% | 30 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $340 → $1,245 | $322.19 | +286.42% | 31 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $105.40 | +11.01% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $22.60 | +68.14% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.05 | +63.93% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $31.29 | +27.84% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.82 | +559.34% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.69 | +494.80% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $35.36 | +30.09% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.50 | +180.00% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $63.94 | +84.55% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $36.32 | +123.02% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.69 | +314.20% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.95 | +823.08% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.99 | +36,448.22% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.02 | +395.05% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $110.66 | +64.47% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $4.69 | +299.79% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $55.31 | -67.46% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $30.12 | -73.44% | 7 | Jun 11, 2019 |
Viridian Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $34 → $22
Current: $19.56
Upside: +12.47%
Minerva Neurosciences
Mar 12, 2026
Maintains: Neutral
Price Target: $4 → $7
Current: $6.03
Upside: +16.18%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $53 → $74
Current: $58.15
Upside: +27.26%
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $8.46
Upside: +18.20%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $16.23
Upside: -7.58%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $27.70
Upside: +22.74%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $730.25
Upside: +28.72%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $23.56
Upside: +44.31%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $45 → $48
Current: $40.23
Upside: +19.31%
Outlook Therapeutics
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.21
Upside: +142.95%
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $24.84
Upside: +40.90%
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.11
Upside: +216.30%
Jan 30, 2026
Maintains: Buy
Price Target: $340 → $1,245
Current: $322.19
Upside: +286.42%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $105.40
Upside: +11.01%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $22.60
Upside: +68.14%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.05
Upside: +63.93%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $31.29
Upside: +27.84%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.82
Upside: +559.34%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.69
Upside: +494.80%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $35.36
Upside: +30.09%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.50
Upside: +180.00%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $63.94
Upside: +84.55%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $36.32
Upside: +123.02%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.69
Upside: +314.20%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.95
Upside: +823.08%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.99
Upside: +36,448.22%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.02
Upside: +395.05%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $110.66
Upside: +64.47%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $4.69
Upside: +299.79%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $55.31
Upside: -67.46%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $30.12
Upside: -73.44%